Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by NPPA belongs to the natriuretic peptide family. Additionally we are shipping Natriuretic Peptide A Kits (134) and Natriuretic Peptide A Proteins (15) and many more products for this protein.
Showing 10 out of 266 products:
Human Polyclonal NPPA Primary Antibody for IHC, IHC (p) - ABIN4282388
Somanna, Yariswamy, Garagliano, Siebenlist, Mummidi, Valente, Chandrasekar: Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2. in Cellular signalling 2015
Show all 2 Pubmed References
Human Polyclonal NPPA Primary Antibody for IF (p), IHC (p) - ABIN676928
Straub, Ehrenstein, Günther, Rauch, Trendafilova, Boschiero, Grifka, Fleck: Increased extracellular water measured by bioimpedance and by increased serum levels of atrial natriuretic peptide in RA patients-signs of volume overload. in Clinical rheumatology 2016
Human Polyclonal NPPA Primary Antibody for FACS, IHC (p) - ABIN652474
Nam, Lubczyk, Bhakta, Zang, Fernandez-Perez, McAnally, Bassel-Duby, Olson, Munshi: Induction of diverse cardiac cell types by reprogramming fibroblasts with cardiac transcription factors. in Development (Cambridge, England) 2014
Human Monoclonal NPPA Primary Antibody for IHC (p), RIA - ABIN2477552
Meyer, Keller, Bur, Hollender: [The giant ulcer of the stomach. Notes concerning 30 cases (author's transl)]. in La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris 1980
Show all 2 Pubmed References
Expression of atrial natriuretic peptide, C-type natriuretic peptide-1, and the guanylyl cyclase-linked (GC) natriuretic peptide receptor-A (show NPR1 Antibodies) and -B-type receptors was determined by PCR from the mRNA of head kidney leucocytes
Atrial natriuretic peptide and vasopressin (show AVP Antibodies)-presence in the ciliary body of eye in the pig (sus domesticus).
ANP and BNP (show BNC2 Antibodies) gene expression differs considerably between cardiac chambers in the first 72 hours of life in healthy piglets, resembling the transition from fetal to neonate circulation. The cardiac gene expression does not explain plasma concentrations.
Up-regulation of ANP and a reduction in a ratio of sarcoplasmic reticulum calcium ATPase (show CA-P60A Antibodies) 2a and phospholamban (show PLN Antibodies) in failing myocardium are observed in a porcine model of tachycardia.
Arial natriuretic factor (ANF (show HESX1 Antibodies)) and N-terminal proANF may be better suited than brain natriuretic peptide (show BNP Antibodies) as markers of cardiac preload during the development and treatment of acute heart failure.
Stimulation of prepubertal granulosa cells with FSH (show BRD2 Antibodies) resulted in a moderate expression of ANP. When FSH (show BRD2 Antibodies) treatment was followed by LH, the pronounced expression of ANP was observed in all cells.
ANP in plasma is increased in horses with heart disease associated with altered left-sided chamber dimensions and/or function.
Cardiac ANP was increased in horses with mitral regurgitation (MR) and cardiac troponin levels were low in healthy and MR affected horses.
Suggest that pro-ANP/corin (show CORIN Antibodies)/NPR-C (show NPR3 Antibodies) signaling is dominant in the vascular system in preeclampsia.
Data indicate the blood pressure-lowering effect of atrial natriuretic peptide (ANP) in the general population.
An increase in year-by-year BP variability over the past 6 years is associated with elevated plasma levels of ANP and BNP (show BNC2 Antibodies) in the Japanese general population.
In summary, there were no significant differences in ANP and BNP (show BNC2 Antibodies) levels after percutaneous epicardial left atrial appendage suture ligation using LARIAT device 3 months after procedure.
NPPA SNPs were not associated with insulin (show INS Antibodies) resistance in older adults.
TIMP-4 (show TIMP4 Antibodies), NT-proANP, NT-proBNP were strongest associated with PAF (show PAF Antibodies) and AHRE (show AHR Antibodies). The discriminatory performance of CHADS2-VASc for PAF (show PAF Antibodies) was increased by addition of selected biomarkers.
ANP inhibits TGF-beta1 (show TGFB1 Antibodies)-induced EMT (show ITK Antibodies) in 16HBE-14o and A549 cells through cGMP/PKG (show PRKG1 Antibodies) signaling, by which it targets TGF-beta1 (show TGFB1 Antibodies)/Smad3 (show SMAD3 Antibodies) via attenuating phosphorylation of Smad3 (show SMAD3 Antibodies). These findings suggest the potential of ANP in the treatment on pulmonary diseases with airway remodeling.
the ANP T1766C gene polymorphism may be associated with the risk of essential hypertension, and the 1766C allele may be a protective factor against the disease
Corin (show CORIN Antibodies) and atrial natriuretic peptide A were most abundant in the proximal convoluted tubules and the medullary connecting ducts.
Higher levels of PCT (show UROD Antibodies), a marker of infection, and MRproANP, a marker for hemodynamic stress, were independently associated with ischemic stroke risk. PCT (show UROD Antibodies) was specifically associated with small vessel and MRproANP with cardioembolic stroke risk.
ANP acts as an anti-permeability factor by inhibiting the signaling functions of vascular permeability factor (show VEGFA Antibodies) and by preserving the endothelial cell tight junctions functional morphology
These studies support the therapeutic potential of dual inhibition of NEP (show MME Antibodies) and ACE (show ACE Antibodies) in the prevention of increased arterial ECP (show ECP Antibodies) and atherogenesis which may be linked to the ANP/cGMP system.
Diabetes may modify the vascular actions of ANP in isolated rabbit carotid arteries and the mechanisms involved in these actions; ANP induces relaxation of precontracted carotid arteries, which is lower in diabetic than in control rabbits.
The study suggests that Beta1-adrenergic receptor activation decreases atrial natriuretic peptide release via cAMP- and Ca(2 (show CA2 Antibodies)+)-dependent mechanisms.
The present study provides a novel insight into the potential underlying mechanisms of telmisartan-induced inhibition of cardiomyocyte hypertrophy, which involves inhibition of NFAT (show NFATC1 Antibodies) activation, nuclear translocation and the ANP/BNP (show BNC2 Antibodies) cascade.
we investigated pregnancies of ANP wild type, heterozygous, and knockout mice. Maternal blood pressure did not differ between genotypes, and fetal weight was unaffected. Placental weight was greater in ANP(-/-) versus ANP(+/+) mice. Therefore, in our hands, the ANP model does not express phenotypic features of preeclampsia with fetal growth restriction.
Data (including data from studies in knockout mice) suggest expression of ANP/BNP (show BNC2 Antibodies)/GC-A (show GUCA1A Antibodies) (atrial natriuretic peptide, brain natriuretic peptide (show BNP Antibodies), and guanylyl cyclase-A (show NPR1 Antibodies)) is important in embryonic neovascularization and organogenesis.
Goalpha plays a role in ANF (show HESX1 Antibodies) sorting during intracellular vectorial transport and with the presence of a mechanism that preserves the molar relationship between cellular ANF (show HESX1 Antibodies) and BNP (show BNC2 Antibodies).
ANP prevents cancer metastasis by inhibiting the adhesion of tumor cells to inflamed endothelial cells
Expression of NPPA splice variants is differentially regulated in the developing mouse heart.
NPPA acts on the NPR1 receptor, is expressed in mouse dorsal root and trigeminal ganglia, and the spinal cord.
Natriuretic peptides buffer renin (show REN Antibodies)-dependent hypertension.
Data indicate that the identified stress-responsive enhancer of Nppa and Nppb (show BNP Antibodies), the most common markers of heart failure, is a 650-bp fragment within 50 kb of the Nppa and Nppb (show BNP Antibodies) loci.
Absence of maternal atrial natriuretic peptide leads to gestational hypertension and adaptive changes fetal cardiac growth and blood pressure regulation.
The protein encoded by this gene belongs to the natriuretic peptide family. Natriuretic peptides are implicated in the control of extracellular fluid volume and electrolyte homeostasis. This protein is synthesized as a large precursor (containing a signal peptide), which is processed to release a peptide from the N-terminus with similarity to vasoactive peptide, cardiodilatin, and another peptide from the C-terminus with natriuretic-diuretic activity. Mutations in this gene have been associated with atrial fibrillation familial type 6.
atrial natriuretic peptide
, atrial natriuretic factor
, natriuretic peptides A
, natriuretic peptide precursor A
, prohormone for atrial natriuretic polypeptide (ANP)
, Natriuretic peptide precursor A (pronatriodilatin, also Anf, Pnd)
, natriuretic peptide precursor type A
, Atrial natriuretic factor
, Atrial natriuretic peptide
, natriuretic peptide type A
, Natriuretic peptides A